Aduro BioTech Company Profile (NASDAQ:ADRO)

About Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech logoAduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADRO
  • CUSIP: N/A
  • Web:
  • Market Cap: $702.63 million
  • Outstanding Shares: 69,913,000
Average Prices:
  • 50 Day Moving Avg: $9.69
  • 200 Day Moving Avg: $11.09
  • 52 Week Range: $8.75 - $16.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.61
  • P/E Growth: 0.06
Sales & Book Value:
  • Annual Revenue: $50.42 million
  • Price / Sales: 13.94
  • Book Value: $3.28 per share
  • Price / Book: 3.06
  • EBIDTA: ($68,020,000.00)
  • Net Margins: -72.04%
  • Return on Equity: -23.45%
  • Return on Assets: -12.40%
  • Current Ratio: 11.11%
  • Quick Ratio: 11.11%
  • Average Volume: 415,783 shs.
  • Beta: 3.83
  • Short Ratio: 21.23

Frequently Asked Questions for Aduro BioTech (NASDAQ:ADRO)

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) posted its quarterly earnings results on Tuesday, May, 2nd. The company reported ($0.32) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.07. The company had revenue of $3.77 million for the quarter, compared to the consensus estimate of $3.74 million. Aduro BioTech had a negative net margin of 72.04% and a negative return on equity of 23.45%. View Aduro BioTech's Earnings History.

When will Aduro BioTech make its next earnings announcement?

Aduro BioTech is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Aduro BioTech.

Where is Aduro BioTech's stock going? Where will Aduro BioTech's stock price be in 2017?

6 brokerages have issued 1-year target prices for Aduro BioTech's stock. Their predictions range from $14.00 to $30.00. On average, they expect Aduro BioTech's stock price to reach $20.00 in the next twelve months. View Analyst Ratings for Aduro BioTech.

What are analysts saying about Aduro BioTech stock?

Here are some recent quotes from research analysts about Aduro BioTech stock:

  • 1. Canaccord Genuity analysts commented, "1Q17 results recap. Adjusted non-GAAP revenue (excluding the individual commercial business) grew 4.4% year over year. Adjusted MLR was 85.2% compared to 85.0% a year ago. MLR benefitted from the exit of certain Medicare markets, which was offset to some degree by lower prior period development when compared to a year ago. Cost trends appear to be in check, consistent with other publicly-traded health insurers." (5/3/2017)
  • 2. According to Zacks Investment Research, "Aduro lead candidate, CRS-207, being evaluated for a number of cancer indications, bodes well for long-term growth. Moreover, its collaboration agreements with Novartis, Johnson & Johnson and Incyte are big positives for the company. Notably, being a development-stage company, Aduro depends largely on funds generated from collaboration and license agreements, government grants and other payments for the development of its pipeline candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Most of its pipeline candidates are in early-to-mid stages of development, which translates into a long way to approval. Any hiccup in the development of its candidates may weigh heavily on the stock. Aduro’s shares have underperformed the Medical-Biomedical/Genetics industry in the last one year. Estimates have been going down lately ahead of Q1 earnings. It has a mixed record of earnings surprise in the last four quarters." (5/2/2017)
  • 3. FBR & Co analysts commented, "Aduro Biotech, Inc.’s (ADRO) cancer immunotherapy platform triggers both innate and adaptive immunity, resulting in a broad and potent multi-pronged immune response. The company’s engineered live, attenuated, double-deleted (LADD) Listeria monocytogenes program is capable of inducing an antigen-specific adaptive T-cell response (CD8+ and CD4+), as well as an innate immune response that includes cytokines, chemokines, gamma delta T cells, and NK cells. The company’s STING (Stimulator of Interferon Genes, driven by cytosolic DNA) platform induces dendritic cells and enhances an anti-tumor T-cell response in the tumor microenvironment. Aduro’s third technology platform is B-select, based on clonal expansion of B cells producing highly selective and functional antibodies against targets that regulate the immune response. Given that the future of cancer immunotherapy points to combinations, Aduro’s programs are complementary combination approaches that activate distinct mechanisms of actions that could be synergistic." (3/7/2017)

Who are some of Aduro BioTech's key competitors?

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who owns Aduro BioTech stock?

Aduro BioTech's stock is owned by many different of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (0.00%), FMR LLC (0.00%), Vanguard Group Inc. (0.00%), Clough Capital Partners L P (0.43%), Baillie Gifford & Co. (0.00%) and Geode Capital Management LLC (0.00%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Dirk G Brockstedt, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro BioTech.

Who sold Aduro BioTech stock? Who is selling Aduro BioTech stock?

Aduro BioTech's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Clough Capital Partners L P, Bank of America Corp DE, Morgan Stanley, ProShare Advisors LLC, JPMorgan Chase & Co., United Services Automobile Association and Credit Suisse AG. Company insiders that have sold Aduro BioTech stock in the last year include Blaine Templeman, Dirk G Brockstedt, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Insider Buying and Selling for Aduro BioTech.

Who bought Aduro BioTech stock? Who is buying Aduro BioTech stock?

Aduro BioTech's stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Goldman Sachs Group Inc., Renaissance Technologies LLC, Highbridge Capital Management LLC, Vanguard Group Inc., Foundry Partners LLC, Piermont Capital Management Inc. and Fox Run Management L.L.C.. View Insider Buying and Selling for Aduro BioTech.

How do I buy Aduro BioTech stock?

Shares of Aduro BioTech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aduro BioTech stock cost?

One share of Aduro BioTech stock can currently be purchased for approximately $10.05.

Analyst Ratings

Consensus Ratings for Aduro BioTech (NASDAQ:ADRO) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (99.00% upside)

Analysts' Ratings History for Aduro BioTech (NASDAQ:ADRO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017Canaccord GenuityReiterated RatingBuy$30.00MediumView Rating Details
5/1/2017HC WainwrightInitiated CoverageBuy$18.00LowView Rating Details
5/1/2017Rodman & RenshawInitiated CoverageBuy -> Buy$18.00LowView Rating Details
3/7/2017FBR & CoReiterated RatingBuy$23.00N/AView Rating Details
3/7/2017Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
10/24/2016Leerink SwannSet Price TargetBuy$14.00N/AView Rating Details
3/15/2016Bank of America CorpDowngradeBuy -> Underperform$32.00 -> $14.00N/AView Rating Details
2/2/2016William BlairInitiated CoverageBuyN/AView Rating Details
12/1/2015Oppenheimer Holdings Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Aduro BioTech (NASDAQ:ADRO)
Earnings by Quarter for Aduro BioTech (NASDAQ:ADRO)
Earnings History by Quarter for Aduro BioTech (NASDAQ:ADRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017($0.39)($0.32)$3.74 million$3.77 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.40)($0.44)$3.83 million$3.88 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.45)($0.54)$3.99 million$3.79 millionViewN/AView Earnings Details
8/3/2016Q2 2016($0.18)$0.03$25.24 million$39.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.25)($0.45)$13.47 million$4.03 millionViewN/AView Earnings Details
3/8/2016Q415($0.15)$0.04$17.55 million$34.38 millionViewN/AView Earnings Details
11/23/2015Q3($0.08)$0.01$15.80 million$19.15 millionViewN/AView Earnings Details
8/10/2015Q215($0.01)($0.18)$1.00 million$9.90 millionViewN/AView Earnings Details
5/28/2015Q115($0.08)($39.97)$12.03 million$9.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aduro BioTech (NASDAQ:ADRO)
2017 EPS Consensus Estimate: ($1.54)
2018 EPS Consensus Estimate: ($1.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.39)($0.35)($0.38)
Q2 20173($0.41)($0.31)($0.38)
Q3 20173($0.43)($0.32)($0.39)
Q4 20173($0.52)($0.32)($0.40)
Q1 20182($0.47)($0.24)($0.36)
Q2 20182($0.47)($0.19)($0.33)
Q3 20182($0.47)($0.20)($0.34)
Q4 20182($0.47)($0.21)($0.34)
(Data provided by Zacks Investment Research)


Dividend History for Aduro BioTech (NASDAQ:ADRO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aduro BioTech (NASDAQ:ADRO)
Insider Ownership Percentage: 6.50%
Institutional Ownership Percentage: 35.52%
Insider Trades by Quarter for Aduro BioTech (NASDAQ:ADRO)
Institutional Ownership by Quarter for Aduro BioTech (NASDAQ:ADRO)
Insider Trades by Quarter for Aduro BioTech (NASDAQ:ADRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Blaine TemplemanVPSell1,648$9.65$15,903.20View SEC Filing  
5/17/2017Dirk G. BrockstedtEVPSell1,011$9.65$9,756.15View SEC Filing  
5/16/2017Stephen T. IsaacsCEOSell16,673$10.00$166,730.00View SEC Filing  
5/16/2017Stephen T. IsaacsinsiderSell27,273$10.01$273,002.73View SEC Filing  
5/15/2017Stephen T. IsaacsCEOSell10,600$10.01$106,106.00View SEC Filing  
5/12/2017Thomas W DubenskyInsiderSell5,699$9.92$56,534.08View SEC Filing  
5/11/2017Dirk G BrockstedtEVPSell8,000$9.72$77,760.00View SEC Filing  
4/3/2017Dirk G BrockstedtEVPSell8,000$10.71$85,680.00View SEC Filing  
4/3/2017Stephen T IsaacsInsiderSell27,273$10.28$280,366.44View SEC Filing  
3/13/2017Stephen T IsaacsInsiderSell27,273$11.35$309,548.55View SEC Filing  
3/9/2017Dirk G BrockstedtEVPSell8,000$11.00$88,000.00View SEC Filing  
3/9/2017Thomas W DubenskyInsiderSell25,000$10.96$274,000.00View SEC Filing  
1/17/2017Dirk G BrockstedtEVPSell8,000$11.86$94,880.00View SEC Filing  
1/11/2017Blaine TemplemanVPSell3,785$11.95$45,230.75View SEC Filing  
1/3/2017Stephen T IsaacsInsiderSell27,273$11.12$303,275.76View SEC Filing  
12/1/2016Thomas W DubenskyInsiderSell25,000$10.94$273,500.00View SEC Filing  
11/14/2016Ross HaghighatDirectorSell7,088$15.50$109,864.00View SEC Filing  
10/3/2016Stephen T IsaacsCEOSell27,273$12.67$345,548.91View SEC Filing  
10/3/2016Thomas W DubenskyInsiderSell25,000$12.68$317,000.00View SEC Filing  
9/19/2016Jennifer LewInsiderSell6,360$14.95$95,082.00View SEC Filing  
9/1/2016Thomas W DubenskyInsiderSell25,000$14.03$350,750.00View SEC Filing  
8/11/2016Thomas W DubenskyInsiderSell25,000$15.18$379,500.00View SEC Filing  
7/5/2016Thomas W DubenskyInsiderSell25,000$11.61$290,250.00View SEC Filing  
5/16/2016Thomas W. DubenskyInsiderSell905$8.20$7,421.00View SEC Filing  
1/11/2016Dirk G. BrockstedtVPSell22,000$21.77$478,940.00View SEC Filing  
1/8/2016Gregory W. SchaferCOOSell20,000$23.58$471,600.00View SEC Filing  
1/6/2016Jennifer LewVPSell5,242$25.71$134,771.82View SEC Filing  
1/5/2016Stephen T. IsaacsCEOSell25,000$26.31$657,750.00View SEC Filing  
1/4/2016Thomas W. DubenskyinsiderSell15,000$26.37$395,550.00View SEC Filing  
12/7/2015Gregory W. SchaferCOOSell25,000$29.74$743,500.00View SEC Filing  
12/3/2015Jennifer LewVPSell5,242$29.85$156,473.70View SEC Filing  
12/1/2015Stephen T. IsaacsCEOSell25,000$29.11$727,750.00View SEC Filing  
12/1/2015Thomas W. DubenskyinsiderSell30,000$29.27$878,100.00View SEC Filing  
11/18/2015Jennifer LewVPSell6,712$28.52$191,426.24View SEC Filing  
11/17/2015Gregory W. SchaferCOOSell26,470$28.15$745,130.50View SEC Filing  
11/17/2015Thomas W. DubenskyinsiderSell31,470$28.27$889,656.90View SEC Filing  
11/16/2015Stephen T. IsaacsCEOSell25,000$27.54$688,500.00View SEC Filing  
4/20/2015Jennifer LewVPBuy2,000$17.00$34,000.00View SEC Filing  
4/20/2015Venture (Vi) Inves MorningsideMajor ShareholderBuy441,176$17.00$7,499,992.00View SEC Filing  
4/20/2015William Mariner GreenmanDirectorBuy3,000$17.00$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aduro BioTech (NASDAQ:ADRO)
Latest Headlines for Aduro BioTech (NASDAQ:ADRO)
DateHeadline logoAduro Biotech to Host and Webcast an Investor Event in Conjunction ... - GlobeNewswire (press release) - May 26 at 3:29 PM logoAduro BioTech Inc (ADRO) Receives Average Rating of "Buy" from Analysts - May 26 at 9:21 AM logoAduro BioTech Inc (ADRO) VP Blaine Templeman Sells 1,648 Shares - May 18 at 10:44 PM logoAduro Biotech Announces Clinical Collaboration with Merck to Evaluate the ... - May 18 at 12:28 PM logoStephen T. Isaacs Sells 10,600 Shares of Aduro BioTech Inc (ADRO) Stock - May 17 at 11:14 PM logoInsider Selling: Aduro BioTech Inc (ADRO) CEO Sells 16,673 Shares of Stock - May 17 at 10:51 PM logoAduro Biotech, Merck Team on Cancer Drug Trial - - May 17 at 8:22 PM logoAduro BioTech Inc (ADRO) Insider Sells $273,002.73 in Stock - May 17 at 7:47 PM logoAduro Biotech, Merck Team on Cancer Drug Trial - May 17 at 3:21 PM logoAduro Biotech (ADRO) Announces Collaboration with Merck (MRK) to Evaluate the Combination of CRS-207 with ... - - May 17 at 12:40 PM logoAduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma - May 17 at 12:40 PM logoAduro BioTech Inc (ADRO) Insider Thomas W. Dubensky Sells 5,699 Shares - May 15 at 8:21 PM logoInsider Selling: Aduro BioTech Inc (ADRO) EVP Sells 8,000 Shares of Stock - May 15 at 8:20 PM logoETFs with exposure to Aduro BioTech, Inc. : May 5, 2017 - May 5 at 8:24 PM logo$3.97 Million in Sales Expected for Aduro BioTech Inc (ADRO) This Quarter - May 5 at 1:58 PM logoWilliam Blair Weighs in on Aduro BioTech Inc's Q2 2017 Earnings (ADRO) - May 5 at 10:18 AM logoLeerink Swann Equities Analysts Boost Earnings Estimates for Aduro BioTech Inc (ADRO) - May 5 at 10:18 AM logoAduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 - May 4 at 3:21 PM logo-$0.41 EPS Expected for Aduro BioTech Inc (ADRO) This Quarter - May 3 at 6:02 PM logoAduro BioTech Inc (ADRO) Releases Earnings Results, Beats Estimates By $0.07 EPS - May 3 at 12:16 PM logoAduro Biotech Reports First Quarter 2017 Financial Results - May 3 at 6:58 AM logoAduro Biotech reports 1Q loss - May 2 at 7:19 PM logoAduro BioTech (ADRO) Earning Somewhat Positive Press Coverage, Study Finds - May 2 at 9:25 AM logoHC Wainwright Begins Coverage on Aduro BioTech Inc (ADRO) - May 1 at 9:08 PM logoAduro BioTech Inc (ADRO) Given Consensus Recommendation of "Buy" by Analysts - May 1 at 12:24 PM logoAduro BioTech Inc (ADRO) Now Covered by Analysts at Rodman & Renshaw - May 1 at 10:27 AM logoAduro BioTech (ADRO) Earns Daily Media Impact Rating of -0.10 - April 29 at 9:00 AM logoAduro BioTech Inc (ADRO) Scheduled to Post Earnings on Monday - April 29 at 1:27 AM logoAduro BioTech Inc (ADRO) Set to Announce Quarterly Earnings on Monday - April 29 at 1:21 AM logoAduro Biotech to Present at Two Investor Conferences in May - April 25 at 3:19 PM logoAduro BioTech (ADRO) Earning Somewhat Favorable News Coverage, Report Shows - April 23 at 7:44 AM logoAduro Biotech Announces Management Promotions - GlobeNewswire (press release) - April 21 at 3:18 PM logoAduro Biotech Announces Management Promotions - April 20 at 8:31 PM logoAduro BioTech (ADRO) Receiving Somewhat Negative Press Coverage, Report Shows - April 20 at 10:41 AM logoAduro BioTech (ADRO) Receiving Very Positive Press Coverage, Analysis Shows - April 17 at 10:08 AM logoAduro BioTech (ADRO) Earning Somewhat Critical Media Coverage, Report Finds - April 14 at 3:48 PM logo Analysts Expect Aduro BioTech Inc (ADRO) to Post -$0.35 Earnings Per Share - April 12 at 2:27 PM logoETFs with exposure to Aduro BioTech, Inc. : April 5, 2017 - April 7 at 6:31 AM logoShort Interest in Aduro BioTech Inc (ADRO) Declines By 2.0% - April 6 at 12:13 PM logoInsider Selling: Aduro BioTech Inc (ADRO) Insider Sells 27,273 Shares of Stock - April 4 at 10:58 PM logoDirk G. Brockstedt Sells 8,000 Shares of Aduro BioTech Inc (ADRO) Stock - April 4 at 10:58 PM logoWhy Is Aduro (ADRO) Down 3.6% Since the Last Earnings Report? - April 3 at 3:29 PM logoQ2 2017 EPS Estimates for Aduro BioTech Inc (ADRO) Lowered by Analyst - March 30 at 9:10 AM logoAduro Biotech, Inc. (Nasdaq: ADRO) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release) - March 28 at 8:20 PM logoAduro BioTech Inc (ADRO) PT Set at $30.00 by Canaccord Genuity - March 28 at 3:40 PM logoAduro Biotech, Inc. (Nasdaq: ADRO) to Ring The Nasdaq Stock ... - Nasdaq - March 28 at 8:01 AM logoAduro Biotech to Host Research and Development Day in New York - March 15 at 3:25 PM logoAduro BioTech Inc (ADRO) Insider Sells $274,000.00 in Stock - March 10 at 9:36 PM logoAduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Community - March 10 at 3:20 PM logoADURO BIOTECH, INC. Financials - March 8 at 3:21 PM



Aduro BioTech (ADRO) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff